MoonLake Immunotherapeutics MLTX Available for sale investments

Available for sale investments at other companies

Oruka Therapeutics, Inc.ORKA

——

Nektar TherapeuticsNKTR

——

Arcutis Biotherapeutics, Inc.ARQT

——

Regeneron PharmaceuticalsREGN

——

GlaukosGKOS

——

Operating income-$70.0M-47.5%

Net income-$69.7M-74.5%

EPS (diluted)-$0.98-55.6%

Cash & equivalents$298.5M+9.9%

Total debt$100.8M+33.3%

Total equity$254.0M-37.7%

Total assets$400.4M-21.7%

Operating cash flow-$66.3M-73.8%

CapEx--100%

Free cash flow-$66.3M-73.6%

Market cap$1.49B-45.9%

Enterprise value$1.29B-50.0%

Return on equity-77.7%-221pp

Debt / equity0.4×+0.2×

Current ratio8.6×-12.5×

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is MoonLake Immunotherapeutics's available for sale investments?: MoonLake Immunotherapeutics (MLTX) reported available for sale investments of $59.43M in Q1 2026.
How has MoonLake Immunotherapeutics's available for sale investments changed year-over-year?: MoonLake Immunotherapeutics's available for sale investments decreased by 71.5% year-over-year, from $208.56M to $59.43M.